Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...

Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...

IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs. Read why ...

Eli Lilly's stock took a noticeable dip following a guidance update from rival Novo Nordisk. Investors reacted sharply as ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo Nordisk stocks plunged by 7% in premarket trading following an announcement by the company that it has lowered its ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Investing.com -- Novo Nordisk (NYSE: NVO )’s guidance reduction and CEO resignation represent a "double surprise" according to BMO Capital Markets analyst Evan David Seigerman. In a note to clients, ...

Novo Nordisk shares plunged more than 20% on the 29th (local time) in New York and Denmark on the 29th (local time) due to the announcement of a slowdown in sales growth of the obesity drug "Wegovy".

The pharma giant cut its guidance and named a new CEO, hoping to revive growth. Its stock fell as much as 30%, wiping almost $93 billion from its market value.

Eli Lilly has been gaining ground on Novo Nordisk in this sector, intensifying the pressure on the company to innovate and regain market share. The leadership change comes at a crucial time as Novo ...